Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ensitrelvir - Shionogi

Next Previous
Drug Profile

Ensitrelvir - Shionogi

Alternative Names: Ensitrelvir fumarate - Shionogi; Ensitrelvir fumaric acid - Shionogi; S-217622; SARS-CoV2 3C-like protease inhibitor - Shionogi; Xocova

Latest Information Update: 23 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hokkaido University; Shionogi
  • Developer Juniper Therapeutics; Shionogi
  • Class Amines; Antivirals; Chlorine compounds; Fluorobenzenes; Indazoles; Ketones; Small molecules; Triazines; Triazoles
  • Mechanism of Action Coronavirus 3C-like proteinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed COVID 2019 infections
  • Clinical Phase Unknown Post acute COVID 19 syndrome

Most Recent Events

  • 03 Apr 2025 Shionogi completes a phase I drug-drug interaction trial (In volunteers) in USA (PO, Tablet) (NCT06775730)
  • 01 Apr 2025 Preregistration for COVID-2019 infections (In adolescents, In the elderly, Prevention, In adults) in USA (PO)
  • 01 Apr 2025 Ensitrelvir - Shionogi receives Fast Track designation for COVID-2019 infections (Prevention) in USA (PO), Before April 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top